Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opiant Pharmaceuticals Inc.

www.opiant.com

Latest From Opiant Pharmaceuticals Inc.

Deal Watch: Gilead Signs Two Deals In Two Days To Increase R&D Emphasis

As it moves away from virology, Gilead’s signs fibrosis collaboration with Scholar Rock. Novartis seeks to acquire CMDO that manufactures Kymriah, while Intrexon regains control of CAR-T program partnered with Merck KGAA. More deals from over the holiday period… 

MyoKardia Frames End Of Sanofi Partnership As A Bet On Itself

Biotech regains full rights to a pair of targeted therapies for heart diseases, but will bear full development costs. MyoKardia says the agreement with Sanofi ended due to differences over commercial rights, not concerns about trial data.

Commercial Cardiovascular

Naloxone Sponsor Steps In Pricing Hole Disputing FDA's Cost Estimates

While arguing that US FDA overestimated inflation and fill rates when calculating annual cost of co-prescribing naloxone with opioids, Adapt Pharma opened door to pricing pledge questions that the Narcan sponsor could not answer.
Advisory Committees Neurology

Finance Watch: Government Grants Galore And Other New Funding Sources

While Forbion's new €360m venture capital fund and other investors have emerged to fund private and public companies, BARDA and other US agencies have been active supporters of biopharma firms in recent weeks. Also, KSQ grabs $80m in VC cash and VelosBios brings in $50m.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Madrona Ventures Inc.
  • Lightlake Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Opiant Pharmaceuticals Inc.
  • Senior Management
  • Roger Crystal, MD, CEO
    David O'Toole, CFO
    Phil Skolnick, PhD, CSO
    Quan Vu, VP, Corp. Dev.
  • Contact Info
  • Opiant Pharmaceuticals Inc.
    Phone: (310) 598-5410
    201 Santa Monica Blvd.
    Ste. 500
    Santa Monica, CA 90401
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register